Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04249284 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT04249284 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 18 participants.
The verdict
NCT04249284, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the pharmacokinetics (the way the body absorbs, distributes and eliminates the drug) of BMS 986165 given in the form of various prototypes of solid tablets to healthy participants.
Interventions
- DRUG BMS-986165
- DRUG BMS-986165 prototype 1
- DRUG BMS-986165 prototype 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-02-06 |
| Est. Completion | 2020-03-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04249284
The ClinicalTrials.gov registry entry for NCT04249284 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which BMS-986165 is the first listed.
NCT04249284 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04249284 about?
NCT04249284 is a clinical study titled "Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants". The purpose of this study is to characterize the pharmacokinetics (the way the body absorbs, distributes and eliminates the drug) of BMS 986165 given in the form of various prototypes of solid tablets to healthy participants.
What is the current status of trial NCT04249284?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2020-02-06. Estimated completion is 2020-03-15.
What interventions are being tested in trial NCT04249284?
The interventions under investigation include: BMS-986165 (DRUG), BMS-986165 prototype 1 (DRUG), BMS-986165 prototype 2 (DRUG).
Who is sponsoring clinical trial NCT04249284?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.